- Home
- GBLI vs XERS Comparison
GBLI vs XERS Comparison
Compare GBLI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- XERS
- Stock Information
- Founded
- GBLI 2016
- XERS 2005
- Country
- GBLI United States
- XERS United States
- Employees
- GBLI N/A
- XERS N/A
- Industry
- GBLI Property-Casualty Insurers
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- GBLI Finance
- XERS Health Care
- Exchange
- GBLI Nasdaq
- XERS Nasdaq
- Market Cap
- GBLI 496.2M
- XERS 500.2M
- IPO Year
- GBLI 2003
- XERS 2018
- Fundamental
- Price
- GBLI $33.62
- XERS $3.20
- Analyst Decision
- GBLI
- XERS Buy
- Analyst Count
- GBLI 0
- XERS 3
- Target Price
- GBLI N/A
- XERS $4.87
- AVG Volume (30 Days)
- GBLI 4.8K
- XERS 1.5M
- Earning Date
- GBLI 11-07-2024
- XERS 03-05-2025
- Dividend Yield
- GBLI 4.16%
- XERS N/A
- EPS Growth
- GBLI 90.04
- XERS N/A
- EPS
- GBLI 2.92
- XERS N/A
- Revenue
- GBLI $442,500,000.00
- XERS $187,361,000.00
- Revenue This Year
- GBLI N/A
- XERS $24.27
- Revenue Next Year
- GBLI $8.39
- XERS $18.57
- P/E Ratio
- GBLI $11.65
- XERS N/A
- Revenue Growth
- GBLI N/A
- XERS 22.72
- 52 Week Low
- GBLI $27.47
- XERS $1.69
- 52 Week High
- GBLI $37.00
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- GBLI 30.49
- XERS 41.57
- Support Level
- GBLI $35.69
- XERS $3.14
- Resistance Level
- GBLI $36.51
- XERS $3.60
- Average True Range (ATR)
- GBLI 0.78
- XERS 0.17
- MACD
- GBLI -0.30
- XERS -0.03
- Stochastic Oscillator
- GBLI 13.51
- XERS 11.32
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.